Business Context and Reporting Period
Company: Integer Holdings Corp (ITGR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended April 3, 2026 (Q1 2026)
Business Overview: Integer is a medical device contract development and manufacturing organization (CDMO) serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. The company operates as a single segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Sales | $439.6 million | $437.4 million |
| Gross Profit | $109.6 million | $120.3 million |
| Gross Margin | 24.9% | 27.5% |
| Operating Income | $31.9 million | $49.6 million |
| Operating Margin | 7.2% | 11.3% |
| Net Income (Continuing Ops) | $16.5 million | ($22.5 million) Loss |
| Diluted EPS | $0.48 | ($0.66) |
| Operating Cash Flow | $24.7 million | $31.3 million |
| Cash & Equivalents (End of Period) | $8.1 million | $31.7 million |
| Long-Term Debt (Net) | $1,251.5 million | $1,185.2 million |
| Available Borrowing Capacity | $729.7 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 0.5% year-over-year, driven by growth in Cardio & Vascular (+1.1%) and Cardiac Rhythm Management & Neuromodulation (+4.9%), partially offset by a 47.3% decline in Other Markets due to the exit of a portable medical product line.
- Margin Compression: Gross margin declined to 24.9% from 27.5%, primarily due to lower fixed cost absorption resulting from reduced production volumes.
- Profitability Turnaround: The company reported a net income of $16.5 million compared to a net loss of $22.5 million in Q1 2025. This improvement is largely attributable to the absence of a $46.7 million debt conversion inducement expense recorded in Q1 2025 and a $5.1 million reduction in interest expense.
- Expense Increases: Operating expenses rose 9.8% to $77.7 million, driven by higher Selling, General, and Administrative (SG&A) costs (up 14.8%) and Research, Development, and Engineering (RD&E) costs (up 14.4%). SG&A increases included $3.2 million in professional fees related to a stockholder activist matter.
- Liquidity: Cash and cash equivalents decreased by $9.0 million to $8.1 million, impacted by a $50.0 million accelerated share repurchase, capital expenditures, and a $14.0 million investment in a convertible debt instrument.
Guidance, Outlook, and Risks
- Sales Outlook: Management expects 2026 year-over-year sales growth to be negatively impacted by lower-than-anticipated market adoption of three new products, a situation described as "highly unusual."
- Strategic Review: In April 2026, the Board initiated a strategic review to maximize stockholder value, considering a full range of opportunities including a sale, merger, or strategic business combination. No definitive timeline or outcome is guaranteed.
- Capital Allocation: The company executed a $50.0 million accelerated share repurchase in Q1 2026. $100 million of capacity remains under the $200 million share repurchase program authorized in November 2025.
- Legal Proceedings: A putative class action securities lawsuit was filed in December 2025 and amended in April 2026, alleging violations of securities laws. The company denies wrongdoing and intends to defend vigorously.
- Debt Covenants: The company remains in compliance with its financial covenants, with a Total Net Leverage Ratio of approximately 3.0:1.0 and an interest coverage ratio of 14.4:1.0 as of April 3, 2026.
Investor Verification Checklist
- Strategic Review Status: Monitor for updates on the strategic review process initiated in April 2026 and potential transaction timelines.
- New Product Adoption: Verify the performance and market adoption rates of the three new products cited as headwinds to 2026 sales growth.
- Activist Costs: Confirm that the $3.2 million in professional fees related to the stockholder activist matter in Q1 2026 represents a one-time expense and that no further costs are anticipated.
- Liquidity Position: Assess the impact of the low cash balance ($8.1 million) relative to the $1.25 billion debt load and the reliance on the revolving credit facility for working capital.
- Legal Exposure: Track the progress of the securities class action lawsuit and any potential settlement or dismissal motions.